Living drugs for gastrointestinal diseases: The case for probiotics

Digestive Diseases

Volumn 24, Issue 1-2, 2006, Pages 137-147

  Marteau, Philippe ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Antibiotic associated diarrhea; Bifidobacterium; Gastroenteritis; Inflammatory bowel disease; Lactobacillus; Probiotics

Indexed keywords

ACTIMEL; AMOXICILLIN; ANTIBIOTIC AGENT; BACTERIAL DNA; CIPROFLOXACIN; CLARITHROMYCIN; INTERLEUKIN 10; LACTASE; LACTEOL FORT; MESALAZINE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RIFABUTIN; RIFAXIMIN; SPERMIDINE; SPERMINE; SUCRASE; TINIDAZOLE; TREFOIL PEPTIDE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VANCOMYCIN; VSL 3; YOGHURT;

ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIGEN PRESENTATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; BILE; CLINICAL TRIAL; CROHN DISEASE; DENDRITIC CELL; DIARRHEA; DISEASE ACTIVITY; DNA MODIFICATION; DRUG SAFETY; ENDOCARDITIS; ENTERITIS; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; EXCESSIVE IMMUNE STIMULATION; FERMENTED PRODUCT; FUNGUS CULTURE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GENE TRANSFER; HOSPITAL INFECTION; HUMAN; ILEITIS; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFECTION; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS JOHNSONII; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; LACTOCOCCUS LACTIS; LACTOSE INTOLERANCE; LIVER ABSCESS; METABOLIC DISORDER; MOLECULAR INTERACTION; MUCOSAL IMMUNITY; NONHUMAN; OXALOBACTER FORMIGENES; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE; STREPTOCOCCUS THERMOPHILUS; SUPERNATANT; WORM EGG;

BIFIDOBACTERIUM; GASTROINTESTINAL DISEASES; HUMANS; LACTOBACILLUS; PROBIOTICS; TREATMENT OUTCOME;

EID: 33646733624     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090317     Document Type: Review

References (92)

1. Schrezenmeir J, de Vrese M: Probiotics, prebiotics and synbiotics - approaching a definition. Am J Clin Nutr 2001;73(2 suppl):361s-364s.
2. Summers RW, Elliott DE, Qadir K, Urban JF Jr, Thompson R, Weinstock JV: Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 2003;98:2034-2041.
3. Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV: Trichuris suis therapy in Crohn's disease. Gut 2005;54:87-90.
4. Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V, Rao AS, Madara JL: Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000;289:1560-1563.
5. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-528.
6. Dahan S, Dalmasso G, Imbert V, Peyron JF, Rampal P, Czerucka D: Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 2003;71:766-773.
7. Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S: Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 2000;47:79-87.
8. Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A: Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 1995;78:491-497.
9. Wehkamp J, Harder J, Wehkamp K Wehkamp-von Meissner B, Schlee M, Enders C, Sonnenborn U, Nuding S, Bengmark S, Fellermann K, Schroder JM, Stange EF: NF-κB- and AP-1-mediated induction of human beta defensin-2 in epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004;72:5750-5758.
10. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H: Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992;32:141-144.
11. Marteau P, Seksik P, Lepage P, Doré J: Cellular and physiological effects of probiotics and prebiotics. Mini-rev Med Chem 2004;4:889-896.
12. Buts JP, De Keyser N, De Raedemaeker L: Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res 1994;36:522-527.
13. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P: Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 2000;68:5998-6004.
14. Resta-Lenert S, Barrett KE: Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003;52:988-997.
15. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA: Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am.J Physiol 1999;276:G941-G950.
16. Bouvier M, Méance S, Bouley C, Berta JL, Grimaud JC: Effects of consumption of a milk fermented with the probiotic strain Bifidobacterium animalis DN-173 010 on colonic transit times in healthy humans. Biosci Microflor 2001;20:43-48.
17. Marteau P, Cuillerier E, Meance S, Gerhardt MF, Myara A, Bouvier M, Bouley C, Tondu F, Bommelaer G, Grimaud JC: Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002;16:587-593.
18. Marteau P, Shanahan F: Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 2003;17:725-740.
19. Fooks LJ, Gibson GR: Probiotics as modulators of the gut flora. Br J Nutr 2002;88(suppl 1):S39-S49.
20. Spanhaak S, Havenaar R, Schaafsma G: The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. Eur J Clin Nutr 1998;52:899-907.
21. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, et al: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-1918.
22. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, Elmer GW: The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-1017.
23. Coconnier MH, Bernet MF, Chauviere G, Servin AL: Adhering heat-killed human Lactobacillus acidophilus, strain LB, inhibits the process of pathogenicity of diarrhoeagenic bacteria in cultured human intestinal cells. J Diarrhoeal Dis Res 1993;11:235-242.
24. Coconnier MH, Lievin V, Hemery E, Servin AL: Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol 1998;64:4573-4580.
25. Marteau P, Flourié B, Pochart P, Chastang C, Desjeux JF, Rambaud JC: Effect of the microbial lactase (EC 3.2.1.23) activity in yoghurt on the intestinal absorption of lactose: an in vivo study in lactase-deficient humans. Br J Nutr 1990;64:71-79.
26. Vesa TH, Marteau P, Korpela R: Lactose intolerance. J Am Coll Nutr 2000;19(2 suppl):165S-175S.
27. Drouault S, Juste C, Marteau P, Renault P, Corthier G: Oral treatment with Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Appl Environ Microbiol 2002;68:3166-3168.
28. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-1355.
29. Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, Rottiers P, Steidler L: Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004;127:502-513.
30. Harms HK, Bertele-Harms RM, Bruer-Kleis D: Enzyme-substitution therapy with the yeast Saccharomyces cerevisiae in congenital sucrase-isomaltase deficiency. N Engl J Med 1987;316:1306-1309.
31. Sidhu H, Allison MJ, Chow JM, Clark A, Peck AB: Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes. J Urol 2001;166:1487-1491.
32. Marteau P, Pochart P, Bouhnik Y, Zidi S, Goderel I, Rambaud JC: Survie dans l'intestin grêle de Lactobacillus acidophilus et Bifidobacterium sp. Ingérés dans unlait fermenté: une base rationnele pouir l'utilisation des probiotiques chez l'homme. Gastroenterol Clin Biol 1992;16:25-28.
33. Bouhnik Y, Pochart P, Marteau P, Arlet G, Goderel I, Rambaud JC: Fecal recovery in humans of viable Bifidobacterium sp. ingested in fermented milk. Gastroenterology 1992;102:875-878.
34. Pochart P, Marteau P, Bouhnik Y, Goderel I, Bourlioux P, Rambaud JC: Survival of Bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am J Clin Nutr 1992;55:78-80.
35. Vesa T, Pochart P, Marteau P: Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment Pharmacol Ther 2000;14:823-828.
36. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH: Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 1993;10:1615-1619.
37. Saxelin M, Pessi T, Salminen S: Fecal recovery following oral administration of Lactobacillus strain GG (ATCC 53103) in gelatine capsules to healthy volunteers. Int J Food Microbiol 1995;25:199-203.
38. Effects of prebiotics and probiotics on flora and immunity in adults. AFSSA report. 2005 (www.afssa.fr).
39. Servin AL, Coconnier MH: Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. Best Pract Res Clin Gastroenterol 2003;17:741-754.
40. Johansson ML, Molin G, Jeppsson B, Nobaek S, Ahrne S, Bengmark S: Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol 1993;59:15-20.
41. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, von Wright A: Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 1999;65:351-354.
42. Mavris M, Sansonetti P: Microbial-gut interactions in health and disease. Epithelial cell responses. Best Pract Res Clin Gastroenterol 2004;18:373-386.
43. Drakes M, Blanchard T, Czinn S: Bacterial probiotic modulation of dendritic cells. Infect Immun 2004;72:3299-3309.
44. Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, Gasbarrini A: Meta-analysis: The effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002;16:1461-1467.
45. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ: Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324:1361-1365.
46. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ: Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002;47:2625-2634.
47. Van Niel CW, Feudtner C, Garrison MN, Christakis DA: Lactobacillus therapy for acute infectious diarrhoea in children: a meta analysis. Pediatrics 2002;109:678-684.
48. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH: Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994;44:1046-1049.
49. Szajewska H, Kotowska M, Mrukowickz JZ: Efficacy of Lactobacillus GG in prevention of nosocomial diarrhoea in infants. J Pediatr 2001;38:361-365.
50. Mastretta E, Longo P, Laccisaglia A, Balbo L, Russo R, Mazzaccara A, Gianino P: Effect of Lactobacillus GG and breast-feeding in the prevention of rotavirus nosocomial infection. J Pediatr Gastroenterol Nutr 2002;35:527-531.
51. Oberhelman RA, Gilman RH, Sheen P, Taylor DN, Black RE, Cabrera L, Lescano AG, Meza R, Madico G: A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. J Pediatr 1999;134:15-20.
52. Hatakka K, Savilahti E, Ponka A, Meurman JH, Poussa T, Nase L, Saxelin M, Korpela R: Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001;322:1327-1329.
53. Pedone C, Bernabeu A, Postaire E, Bouley A, Reinert P: The effect of supplementation with milk fermented by Lactobacillus casei (strain DN-114 001) on acute diarrhoea in children attending day care centres. Int J Clin Pract 1999;53:179-184.
54. Pedone CA, Arnaud CC, Postaire ER, Bouley CF, Reinert P: Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int J Clin Pract 2000;54:568-571.
55. Kolars JC, Levitt MD, Aouji M, Savaiano DA: Yogurt - an autodigesting source of lactose. N Engl J Med 1984;310:1-3.
56. Arrigoni E, Marteau P, Briet F, Pochart P, Rambaud JC, Messing B: Tolerance and absorption of lactose from milk and yogurt during short-bowel syndrome in humans. Am J Clin Nutr 1994;60:926-929.
57. Felley CP, Corthesy-Theulaz I, Rivero JL, Sipponen P, Kaufmann M, Bauerfeind P, Wiesel PH, Brassart D, Pfeifer A, Blum AL, Michetti P: Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001;13:25-29.
58. Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F, Pola P, Gasbarrini G, Gasbarrini A: A lyophilised and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000;14:1625-1629.
59. Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetti V, Cammarota G, Anti M, De Lorenzo A, Pola P, Gasbarrini G, Gasbarrini A: The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001;15:163-169.
60. Oksanen PJ, Salminen S, Saxelin M, Hamalainen P, Ihantola-Vormisto A, Muurasniemi-Isoviita L, Nikkari S, Oksanen T, Porsti I, Salminen E, et al: Prevention of travellers' diarrhoea by Lactobacillus GG. Ann Med 1990;22:53-56.
61. Hilton E, Kolakowski P, Singer C, Smith M: Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J Travel Med 1997;4:41-43.
62. Kollaritsch H, Holst H, Grobara P, Wiedermann G: Prevention of traveler's diarrhea with Saccharomyces boulardii: results of a placebo controlled double-blind study (in German). Fortschr Med 1993;111:152-115.
63. Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-1633.
64. Marteau P, Lepage P, Mangin I, Suau A, Dore J, Pochart P, Seksik P: Review article: gut flora and inflammatory bowel disease. Aliment Pharmacol Ther 2004;20(suppl 4):18-23.
65. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-309.
66. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-114.
67. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-1209.
68. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-858.
69. Rembacken BJ, Snelling AM, Hawkey PM , Chalmers DM, Axon AT: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-639.
70. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-1623.
71. Malchow HA: Crohn's disease and Escherichia coli: a new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25:653-658.
72. Guslandi M, Mezzi G, Sorghi M, Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-1464.
73. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-409.
74. Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini F, Helwig U: Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology 2000;118:G4179.
75. Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soulé JC, Boureille A, Metman E, Lerebours E, Carbonnel F, Dupas JL, Veyrac M, Coffin B, Moreau J, Mary JY, GETAID: Ineffectiveness of the probiotic strain Lactobacillus johnsonii LA1 in preventing recurrence after curative resection for Crohn's disease: a randomized double-blind, placebo controlled trial (abstract). Gastroenterology 2005;128:47541.
76. Meance S, Cayuela C, Turchet P, Raimondi A, Lucas C, Antoine JM: A fermented milk with a Bifidobacterium probiotic strain DN-173010 shortened oro-fecal gut transit time in elderly. Microbial Ecol Health Dis 2001;13:217-222.
77. Halpern GM, Prindiville T, Blanckenburg M, Hsia T, Gerschwin ME: Treatment of irritable bowel syndrome with Lacteol fort: a randomized, double-blind, cross-over trial Am J Gastroenterol 1996;91:1579-1585.
78. O'Sullivan MA, O'Morain CA: Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000;32:294-301.
79. Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard JP, Ricour C, Jacquemin JL, Berche P: Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000;19:16-20.
80. Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, Koskela M: Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-1160.
81. Land MH, Rouster-Stevens K, Wood CR, Cannon ML, Cnota J, Shetty AK: Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-181.
82. Lherm T, Monet C, Nougiere B, Soulier M, Larbi D, Le Gall C, Caen D, Malbrunot C: Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intens Care Med 2002;28:797-801.
83. Cassone M, Serra P, Mondello F, Girolamo A, Scafetti S, Pistella E, Venditti M: Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003;41:5340-5343.
84. Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M, Valtonen V: Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003;36:775-780.
85. MacKay A, Taylor M, Kibbler C, Hamilton Miller J: Lactobacillus endocarditis caused by a probiotic microorganism. Clin Microbiol Infect 1999;5:290-292.
86. Steidler L: Genetically engineered probiotics. Best Pract Res Clin Gastroenterol 2003;17:861-876.
87. Arvola T, Laiho K, Torkkeli S, Mykkanen H, Salminen S, Maunula L, Isolauri E: Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999;104:e64.
88. Gotz V, Romankiewicz JA, Moss J, Murray HW: Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. Am J Hosp Pharm 1979;36:754-757.
89. Lewis SJ, Potts LF, Barry RE: The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998;36:171-174.
90. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL: Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439-448.
91. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G: Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989;96:981-988.
92. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ: Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999;135:564-568.